pancreatic%20cancer
PANCREATIC CANCER
Pancreatic cancer is malignancy arising from the pancreas.
It is the 13th most common cancer in the world, 10th most common in the United States, and 4th leading cause of cancer-related deaths in the United Stated and Europe.
Exocrine tumors account for 95% of malignant pancreatic disease.
It is more common in women.
The median age of occurrence is at 71 years old.

Radiotherapy

Neoadjuvant Therapy

Radiation Therapy

  • Recommended radiotherapy regimens post-chemotherapy:
    • Gemcitabine-based (preferred)
    • Continuous infusion 5-FU-based
    • Capecitabine-based
  • Recommended dose:
    • 45-54 Gy in 1.8-2.5 Gy fractions
      • Recommended to be given as a postoperative treatment w/ high-energy protons >4 MV to the tumor bed, surgical anastomoses & adjacent lymph node regions
      • A follow-up dose of 5-15 Gy to the tumor bed is recommended after standard dose
    • 36 Gy in 2.4 Gy fractions
  • Doses of >54 Gy may be given for patients w/ higher stages or if clinically appropriate

Adjuvant Therapy

  • Adjuvant radiation therapy w/ concurrent fluoropyrimidine therapy is not routinely recommended if surgical margin is negative

For patients w/ locally resectable tumors

  • Regimens for radiation therapy include:
    • Capecitabine-based
    • Continuous infusion 5-FU-based
    • Fluoropyrimidine-based
    • Gemcitabine-based
    • Gemcitabine or bolus 5-FU/Leucovorin
    • Gemcitabine or bolus 5-FU/Leucovorin followed by continuous infusion 5-FU or Capecitabine-based chemoradiation therapy (CRT)

For patients w/ borderline resectable tumors

  • Recommended regimens for radiation therapy include:
    • Gemcitabine-based (preferred)
    • Continuous infusion 5-FU-based
    • Capecitabine-based

For patients w/ locally advanced tumors

  • A fluoropyrimidine- or gemcitabine-based chemoradiotherapy is a reasonable alternative in select patients w/o systemic metastases
  • Patients w/ local disease causing uncontrolled pain can be considered for upfront chemoradiotherapy
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.